Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone for patients with this serious condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/go3BxmL
via IFTTT

Read More

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts for a significant portion of the global dengue burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eYgG18d
via IFTTT

Read More

Alcon to step up India investments; focus on innovation, training, says Senior Vice Prez Rajkumar Narayanan

Alcon is significantly increasing its investments in India's eye care market. The company sees India as a crucial emerging growth market for its future. Rising eye disorders among younger Indians are a key driver for Alcon's expansion. Alcon plans to enhance innovation and surgeon training programs across the nation. Future manufacturing in India is also being actively evaluated by the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Amds2LF
via IFTTT

Read More

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4 billion. Commercial launch depends on ongoing litigation, marking a regulatory milestone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4tEAoYG
via IFTTT

Read More

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pCcdEbT
via IFTTT

Read More

Screens are straining young eyes, and Alcon sees India's opportunity

Alcon is increasing investments in India, recognizing its significant emerging market potential. The company focuses on innovation and surgeon training to address rising eye care needs. India's large population and growing myopia present substantial future growth opportunities. Alcon aims to enable advanced cataract care for millions by the year 2030. The global eye care leader is also evaluating future manufacturing possibilities within India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3T1AC4
via IFTTT

Read More

Poly Medicure bets on new facilities, products to double international business: MD

The company's international business contributed ₹1,280.2 crore in FY26, accounting for nearly 68% of the company's total revenue of ₹1,875.3 crore. It expects the next phase of growth to be supported by two upcoming manufacturing facilities, a pipeline of more than 50 products, and a sharper focus on direct-market operations across key overseas geographies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VupHFhy
via IFTTT

Read More